

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

RESIGNATION OF DIRECTOR AND SUPERVISOR AND PROPOSED APPOINTMENT OF DIRECTOR AND SUPERVISOR

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

RESIGNATION OF A DIRECTOR AND A SUPERVISOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that, (i) Dr. Hai Lu (陸海) (“**Dr. Lu**”) has tendered his resignation as a non-executive Director with effect from the conclusion of the forthcoming annual general meeting of the Company (the “**AGM**”), due to other work commitment; and (ii) Mr. Chunhui Men (門春輝) (“**Mr. Men**”) has tendered his resignation as a shareholders’ representative supervisor of the Company with effect from the conclusion of the AGM, due to other work commitment.

Dr. Lu has confirmed that he has no disagreement with the Company and the Board. Mr. Men has confirmed that he has no disagreement with the Company, the Board and the supervisory committee of the Company (the “**Supervisory Committee**”). Both Dr. Lu and Mr. Men have confirmed that there are no other matters relating to their resignations that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to thank Dr. Lu and Mr. Men for their valuable contributions to the Company.

PROPOSED APPOINTMENT OF A DIRECTOR

The Board is pleased to announce that during its meeting held on April 7, 2022, it has resolved to nominate Mr. Dongfang Li (李東方) (“**Mr. Li**”) as a candidate for non-executive Director of the first session of the Board. In accordance with the requirements of relevant laws, regulations, regulatory rules and the articles of association of the Company (the “**Articles of Association**”), the proposed appointment of Director is subject to the approval by the Shareholders at the general meeting. The relevant ordinary resolution will be put forward at the AGM for Shareholders’ consideration and approval.

The biographical details of Mr. Li is as follows:

Mr. Dongfang Li (李東方), aged 34, has served as an executive director of SDIC Fund Management Co., Ltd. (國投創新投資管理有限公司) since August 2015, focusing on investments on the healthcare industry. Before joining SDIC Fund Management Co., Ltd., he served as an analyst in the global investment research department of Goldman Sachs (Asia) LLC (高盛 (亞洲) 有限責任公司) from August 2011 to March 2015. Mr. Li has also served as a director of Suzhou Ribo Life Science Co., Ltd. (蘇州瑞博生物技術股份有限公司) since October 2018, a director of EpimAb Biotherapeutics Inc. since June 2016, and a director of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (四川科倫博泰生物醫藥股份有限公司) since March 2021.

Mr. Li received a bachelor’s degree in management from the University of International Business and Economics in 2009 and a master’s degree in economics from the University of International Business and Economics in 2011. Mr. Li has been a chartered financial analyst since June 2015.

Taking into consideration of the diversity perspectives (including but not limited to gender, age, cultural and educational background, professional experience, length of service, skills and knowledge), the Board is satisfied that Mr. Li is of such character, integrity and experience commensurating with the office of a non-executive Director.

The term of office of Mr. Li shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Board. Mr. Li shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a three-year service contract with Mr. Li upon approval at the AGM. Mr. Li will not receive any remuneration from the Company for acting as a non-executive Director.

Save as disclosed above and as at the date of this announcement, Mr. Li does not have any relationship with any director, supervisor, senior management or substantial Shareholders of the Company, nor does he hold any other positions in the Company or any of its subsidiaries, or hold any directorships in other listed companies in the last three years.

As at the date of this announcement, Mr. Li does not have or is not deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance) (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

Save as disclosed above and as at the date of this announcement, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Li that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

PROPOSED APPOINTMENT OF A SUPERVISOR

The Supervisory Committee has resolved on April 7, 2022 to nominate Mr. Tao Liu (劉濤) (“**Mr. Liu**”) as a candidate for shareholders’ representative supervisor of the first session of the Supervisory Committee. In accordance with the requirements of relevant laws, regulations, regulatory rules and the Articles of Association, the proposed appointment of Shareholders’ representative supervisor is subject to the approval by the Shareholders at the general meeting. The relevant ordinary resolution will be put forward at the AGM for Shareholders’ consideration and approval.

The biographical details of Mr. Liu is as follows:

Mr. Tao Liu (劉濤), aged 42, has served as a vice president of the registration and regulatory affairs department of the Company since January 2021. Before joining the Company, Mr. Liu served as the director of the China registration and regulatory affairs department in Edwards Lifesciences China, leading the entire China registration and regulatory affair team, from June 2016 to December 2020, and worked in the China medical registration and regulatory affairs department at Johnson & Johnson Medical China from 2006 to 2016.

Mr. Liu received a bachelor’s degree in Bio-Chemical Engineering from Beijing University of Chemical Technology in 2002.

The term of office of Mr. Liu shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Supervisory Committee. Mr. Liu shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a three-year service contract with Mr. Liu upon approval at the AGM. Mr. Liu will not receive any remuneration from the Company for acting as the Shareholders’ representative supervisor.

Save as disclosed above and as at the date of this announcement, Mr. Liu does not have any relationship with any director, supervisor, senior management or substantial Shareholders of the Company, nor does he hold any other positions in the Company or any of its subsidiaries, or hold any directorships in other listed companies in the last three years.

As at the date of this announcement, Mr. Liu does not have or is not deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO).

Save as disclosed above and as at the date of this announcement, the Supervisory Committee is not aware of any other matters in relation to the proposed appointment of Mr. Liu that needs to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 7, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji., Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.